Skip to main content

Table 4 Episodes of adverse events reported at Kibaha and Ujiji

From: High cure rates and tolerability of artesunate–amodiaquine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma, Tanzania

AEs

Kibaha

Ujiji

Total (n = 223)

DP (n = 73)

ASAQ (n = 38)

DP (n = 62)

ASAQ (n = 50)

Cough

37 (50.7)

19 (50.0)

15 (24.2)

16 (32.0)

87 (39.0)

Running nose

15 (20.5)

3 (7.9)

7 (11.3)

8 (16.0)

33 (14.8)

Abdominal pain

4 (5.5)

2 (5.3)

6 (9.7)

4 (8.0)

16 (7.2)

Diarrhoea

2 (2.7)

1 (2.6)

7 (11.3)

6 (12.0)

16 (7.2)

Fever

3 (4.1)

1 (2.6)

8 (12.9)

3 (6.0)

15 (6.7)

Vomiting

3 (4.1)

0 (0)

3 (4.8)

3 (6.0)

9 (4.0)

Skin itching

3 (4.1)

1 (2.6)

3 (4.8)

0 (0)

7 (3.1)

Painful micturition

0 (0)

1 (2.6)

4 (6.5)

1 (2.0)

6 (2.7)

Painful ear

1 (1.4)

1 (2.6)

2 (3.2)

2 (4.0)

6 (2.7)

Difficulty in breathing

0 (0)

0 (0)

1 (1.6)

4 (8.0)

5 (2.2)

Others

5 (6.8)

9 (23.7)

6 (9.7)

3 (6.0)

23 (10.3%)

  1. n = number of episodes